Market Intelligence Ecosystem
VIMTA LABS LTD (NSE:VIMTALABS) Q4 FY23 Earnings Concall dated May. 05, 2023. Corporate Participants: Vishal Manchanda -- Vice President, Institutional Research Narahari Naidu -- Chief Financial
Jyothy Laboratories Limited (NSE:JYOTHYLAB) Q4 FY23 Earnings Concall dated May. 03, 2023. Corporate Participants: Sanjay Agarwal -- Chief Financial Officer M R Jyothy -- Managing Director
Rossari Biotech Ltd (NSE:ROSSARI) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Aesha Shah -- Investor Relations Edward Menezes -- Executive Chairman & Co-Founder
Meghmani Organics Limited (NSE:MOL) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Ankit Patel -- Chief Executive Officer Gurjant Singh Chahal -- Chief Financial
RPG LIFE SCIENCES LTD (NSE:RPGL) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Yugal Sikri -- Managing Director Analysts: Sudarshan Padmanabhan -- JM Financial
Aarti Drugs Limited (NSE:AARTIDRUGS) Q4 FY23 Earnings Concall dated May. 02, 2023. Corporate Participants: Adhish Patil -- Chief Financial Officer Harshit M. Savla -- Joint Managing
Glenmark Life Sciences Limited (NSE:GLS) Q4 FY23 Earnings Concall dated Apr. 28, 2023. Corporate Participants: Soumi Rao -- General Manager, Corporate Communications Yasir Rawjee -- Managing
https://youtu.be/5Vtl-XMN8qg Key highlights from Laurus Labs Limited (LAURUSLABS) Q4 FY23 Earnings Concall Management Update: [00:09:24]LAURUSLABS said it invested in expanding non-ARV formulation
Laurus Labs Limited (NSE:LAURUSLABS) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Satyanarayana Chava -- Founder & Chief Executive Officer V V
Dhampur Bio Organics Ltd (NSE:DBOL) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Mr. Navin Agrawal -- Head of Institutional Equities Nalin
Syngene International Ltd (NSE:SYNGENE) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Avantika Mishra -- Investor Relations Jonathan Hunt -- Managing Director and Chief
To meet the demands of the international pharmaceutical industry, Laurus Labs primarily provides a comprehensive and integrated portfolio of Active Pharmaceutical Ingredients
Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of 31%.While, consolidated
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Nath Bio-Genes (India) Limited (NSE:NATHBIOGEN) Q4 FY23 Earnings Concall dated Apr. 24, 2023. Corporate Participants: Unidentified Speaker -- Devinder Khurana -- Chief Financial Officer Satish
Panacea Biotec Limited is an Indian pharmaceutical company that is engaged in research, development, and manufacturing of pharmaceuticals, vaccines, and natural products.
“I am happy to report that our hospital business continued to deliver consistent performance in all key operational and financial parameters with
“In FY24, Company’s profitability is expected to improve, driven by growth in Radiopharmaceuticals, Allergy Immunotherapy and CDMO Sterile Injectables businesses. Recovery in
“Strategic priority is to enhance our free cash generation and further debt reduction and we continue discussion with potential partners for out-licensing
Key highlights from Neuland Laboratories Limited (NEULANDLAB) Q3 FY23 Earnings Concall Management Update: [00:05:35] NEULANDLAB said its raw material prices are becoming
Key highlights from Sequent Scientific Limited (SEQUENT) Q3 FY23 Earnings Concall Management Update: [00:05:37] SEQUENT said that in the API business, the